Related Experiment Videos
[Fundamental and clinical studies on ceftazidime in the field of paediatrics]
Insights
Ceftazidime (CAZ) shows high effectiveness against Gram-negative bacteria in pediatric patients, with rapid excretion and no observed side effects. This new injectable antibiotic demonstrates excellent clinical outcomes in initial trials.
Area of Science:
- Pharmacology
- Microbiology
- Pediatrics
Context:
- Ceftazidime (CAZ) is an injectable cephem antibiotic.
- Pediatric applications of novel antibiotics require thorough evaluation.
Purpose:
- To evaluate the antibacterial spectrum, pharmacokinetics, and clinical efficacy of Ceftazidime in pediatric patients.
Summary:
- Ceftazidime exhibits potent activity against Gram-negative rods, including Pseudomonas aeruginosa, while showing moderate activity against Gram-positive cocci.
- The drug is rapidly absorbed and excreted, with over 90% eliminated within 6 hours post-administration.
- Clinical efficacy was rated as excellent or good in all 4 treated pediatric cases, with no adverse effects reported.
Impact:
- Ceftazidime presents a promising therapeutic option for pediatric infections caused by susceptible Gram-negative pathogens.
- The favorable pharmacokinetic profile and safety suggest potential for widespread use in pediatric infectious disease management.
Abstract:
Ceftazidime (CAZ), a new cephem antibiotic for injection, was used in the field of paediatrics, and the following results were obtained. Antibacterial activity of CAZ was high against Gram-negative rods including P. aeruginosa, but slightly low against Gram-positive cocci. Absorption and excretion of CAZ were rapid, and 90% or more was excreted at 6 hours after administration. The clinical efficacy was excellent or good in all the 4 cases treated with CAZ, and no side effects were observed.